English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

• Oral agents available for the treatment of MRSA, such as linezolid (100.0% susceptible), tetracycline (92.5–96.9% susceptible), and trimethoprim-sulfamethoxazole (TMP-SMX; 96.2–99.6% susceptible), were active against CA-MRSA subsets from adult and pediatric patients, whereas clindamycin (69.7–89.8% susceptible) had suboptimal antimicrobial coverage (Figure 2) • Erythromycin (10.2–16.2% susceptible) and levofloxacin (28.7–48.3% susceptible) were not active against the CA-MRSA subsets; hence, they are not recommended for the empiric coverage of such pathogens (Figure 2) • Tedizolid MIC results were 2to 4-fold lower than those obtained for IV options such as daptomycin (MIC50/90, 0.25/0.5 μg/mL) and 8-fold lower than obtained for linezolid (MIC50/90, 1/1 μg/mL), ceftaroline (MIC50/90, 1/1 μg/mL), and vancomycin (MIC50/90, 1/1 μg/mL) against CA-MRSA and population subsets (data not shown)

open forum infectious diseases

In Vitro Activity of Tedizolid in Comparison With Other Oral and Intravenous Agents Against a US Collection of Community-Acquired Methicillin-Resistant Staphylococcus aureus (2014–2015)